RCT1100 clinical trials
Also written RCT1100.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses RCT1100 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RCT1100
- 3
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
ReCode Therapeutics (3)
Studies
Open first, then newest update. How each study uses RCT1100 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary ClearanceCompletedPhase 1ReCode TherapeuticsNCT06633757Written as RCT1100
- A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCDCompletedPhase 1ReCode TherapeuticsNCT06600425Written as RCT1100
- Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD SubjectsCompletedPhase 1ReCode TherapeuticsNCT05737485Written as RCT1100